Jaykay Enterprises Limited announced that its wholly owned subsidiary, JK Digital & Advance Systems Private Limited, has received a licence from the Central Drugs Standard Control Organisation (CDSCO) to manufacture Class C and Class D medical devices. The approval, dated October 21, 2026, authorises the production of specialised orthopaedic and spinal implants under the brand names Neobone and Nubone.

The licence, bearing number MFG/MD/2026/000784, was issued under the Medical Devices Rules, 2017. This regulatory milestone enables JK Digital to commercially produce advanced titanium alloy implants designed for complex hip revision surgeries and spinal fusion procedures.

Product portfolio and specifications

The licensed products are manufactured using titanium alloy powder (Ti6Al4V) and are sterilized for clinical use. The approval covers eight distinct categories of implants, primarily focused on acetabular reconstruction and spinal interbody fusion.

All devices listed have a shelf life of two years and are intended for single-use implantation. The spinal implants, including TLIF and PLIF cages, are designed to restore disc height and maintain spinal alignment while packed with autograft or allograft bone.

Regulatory validity and impact

According to the disclosure filed with stock exchanges, the manufacturing licence is valid for a lifetime, subject to compliance with the terms and conditions prescribed by the CDSCO. The company stated that this development strengthens its presence in the specialised medical devices segment and provides a regulatory foundation for pursuing opportunities in advanced orthopaedic and spinal implant solutions.

What the numbers show

The disclosure highlights a strategic shift towards high-value, regulated healthcare products. By securing a lifetime licence for Class C devices, which carry higher regulatory scrutiny than Class A or B, JK Digital positions itself in a niche market requiring significant technical expertise in additive manufacturing (lattice structures). The reliance on Ti6Al4V titanium alloy indicates a focus on durable, biocompatible implants suitable for load-bearing applications like hip and spine surgery, differentiating the product line from lower-tier consumables.

Jaykay Enterprises has executed a loan agreement with its wholly owned subsidiary, JK Defence & Aerospace Limited, for an amount of up to ₹100 crore. The transaction, structured as an unsecured inter-corporate deposit, carries an interest rate of 10% per annum.

The agreement was signed on October 8, 2026. The funds are designated for use by the subsidiary in the defence and aerospace sector. Disbursement will occur in one or more tranches, rather than as a single lump sum payment.

Key terms of the loan agreement

The disclosure highlights that the loan is unsecured, meaning no collateral has been pledged by the borrower. The tenure of the agreement is fixed at three years. Repayment of the principal along with accrued interest will follow terms mutually agreed upon by both parties.

Nature of the transaction

The loan constitutes a related-party transaction between the parent company and its subsidiary. Jaykay Enterprises holds 100% equity in JK Defence & Aerospace. The company stated that the transaction is conducted on an arm's length basis. As of the date of the agreement, there were no outstanding loans from Jaykay to JK Defence excluding this new facility.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details have been hosted on the company’s website for public record.